Caris Life Sciences, Inc. (CAI)

Caris Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	32.7	65.44	60.01
Short-Term Investments	2.23	2.2	65.18
Cash & Cash Equivalents	34.93	67.64	125.19
Cash Growth	-	-45.97%	-
Receivables	80.17	88.24	55.3
Other Current Assets	56.13	59.84	62.12
Total Current Assets	171.23	215.73	242.61
Property, Plant & Equipment	-	67.82	107.09
Goodwill and Intangibles	-	19.34	19.34
Other Long-Term Assets	-	40.84	43.86
Total Long-Term Assets	-	128.01	170.29
Total Assets	-	343.73	412.9
Accounts Payable	-	27.79	26.68
Current Debt	-	60.09	0.17
Other Current Liabilities	162.55	77.54	68.29
Total Current Liabilities	162.55	165.42	95.14
Long-Term Debt	-	319.44	166.42
Other Long-Term Liabilities	-	136.06	171.01
Total Long-Term Liabilities	-	455.5	337.43
Total Liabilities	-	620.92	432.57
Total Debt	376.74	379.53	166.59
Debt Growth	-	127.82%	-
Retained Earnings	-	-2,472	-2,119
Comprehensive Income	-	0.21	0.22
Shareholders' Equity	-2,600	-2,499	-2,145
Net Cash / Debt	-341.81	-311.89	-41.4
Working Capital	8.68	50.31	147.47

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).